#AASLD25: Rivus’ MASH drug cuts liver fat, preserves muscle in mid-stage trial

CMS unveils new Medicaid drug payment model

CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump’s “most

FDA says it raised concerns about Biohaven’s ataxia study several times since it was proposed

The FDA told Biohaven its study using real-world data “would likely be inadequate to provide substantial evidence of effectiveness” when it was proposed, according to

Gilead’s Trodelvy fails Phase 3 breast cancer study

Gilead’s Trodelvy failed to meet the primary endpoint in a Phase 3 trial for certain breast cancer patients, marking another setback for a key drug

#SITC25: Akeso, Summit’s PD-1xVEGF drug extends life in China lung cancer study

Researchers reported that adding Akeso and Summit Therapeutics’ ivonescimab to chemotherapy cut the risk of death by 26% in a study conducted in China for

Sana suspends work on allogeneic CAR-T; Biokin eyes $387M raise in Hong Kong

Plus, news about Codexis, Gilead, nChroma Bio, Bavarian Nordic, UroGen, Agenus, Accipiter Biosciences and Immunocore: ✂️ Sana trims cell therapy pipeline: The Seattle-based biotech is